secwatch.observer — SEC 8-K summary
======================================

Issuer:     ARVINAS, INC. (ARVN)
CIK:        0001655759
Form:       8-K
Filed at:   2022-11-09T23:59:59+00:00
Accession:  0001655759-22-000053
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arvinas Q3 net loss widens to $66.2M; cash at $1.28B; on track for Phase 3 starts
--------------------------------------------------------------------------------

- Net loss of $66.2M for Q3 2022 vs $46.8M in Q3 2021, driven by higher R&D and G&A costs.
- Cash, cash equivalents and marketable securities were $1,276.2M as of Sept 30, 2022, sufficient beyond 2024.
- R&D expenses nearly doubled to $77.5M, reflecting investment in platform and ER/AR programs.
- On track to initiate two Phase 3 trials for ARV-471 in metastatic breast cancer by end of 2022.
- Revenue from Pfizer collaboration drove revenues to $30.3M from $9.3M year-over-year.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1655759/000165575922000053/0001655759-22-000053-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1655759/000165575922000053/arvn-20221108.htm
  HTML page:      https://secwatch.observer/filing/0001655759-22-000053

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer